REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 419.60
Bid: 419.50
Ask: 419.80
Change: 11.90 (2.92%)
Spread: 0.30 (0.072%)
Open: 417.60
High: 420.20
Low: 415.10
Prev. Close: 407.70
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3rd Quarter Trading Update

17 Oct 2019 07:00

RNS Number : 1461Q
Rentokil Initial PLC
17 October 2019
 

  

17 October 2019

RENTOKIL INITIAL PLC - THIRD QUARTER TRADING UPDATE

 

Another strong quarter: Ongoing Organic Revenue growth of 5.5% our highest level in over 10 years, continued progress in M&A, on track to meet expectations for the full year

 

 

(£m)

Q3 2019

Growth

AER

AER

CER

Ongoing Revenue1

723.0

13.6%

9.8%

Revenue

727.2

13.4%

9.6%

 

Overview (CER)

 

Ongoing Revenue increased by 9.8% in Q3, of which 5.5% was Organic2 (H1 2019: 4.2%, Q3 2018: 4.1%) and 4.3% was from acquisitions.

Ongoing revenue in Pest Control grew by 12.3% (5.9% Organic), with good performances delivered across both Growth and Emerging markets, which grew by 12.2% and 12.7% respectively. Our North American, UK & Rest of World and Latin American operations delivered particularly good growth in the period.

Our Hygiene business performed well during the quarter, with Ongoing Revenue increasing by 5.5%, and Organic Revenue rising by 4.8%. This reflects good growth in the UK, Europe and Pacific and the ongoing contribution from acquisitions.

Ongoing Revenue in our Protect & Enhance category grew by 4.9% (4.5% Organic), reflecting a solid performance from both France Workwear and Ambius, and an improved performance from our UK Property Care business which encouragingly delivered positive growth.

During the third quarter the Company undertook its biennial survey of our 40,000 colleagues around the world. 90% of our colleagues participated and the results continued to place Rentokil Initial in the global High Performance group of leading companies for both Colleague Engagement and Enablement.

M&A

​We acquired 15 businesses in the quarter across all of our regions (except Pacific), with annualised revenues of c. £15m. 12 Pest Control businesses were acquired, predominantly in North America and Latin America. For the year to 30 September 2019 we have acquired a total of 32 businesses (24 in Pest Control, five in Hygiene and three in Protect & Enhance) primarily in Emerging and Growth markets. Annualised revenues of the businesses acquired so far in 2019 totalled c. £70m in the year prior to purchase. Our M&A pipeline going into Q4 and 2020 remains strong.

Conclusion of CMA reviews

 

The CMA's reviews into the acquisitions of Cannon UK and MPCL (formerly Mitie Pest) concluded on 30 September following completion of the partial divestments required on each by the CMA. Integration of the retained businesses is now proceeding at pace.

​Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with our Q3 results and our Group Organic Growth of 5.5% is our highest level of quarterly Organic Growth in over a decade. Pest Control has performed well, growing organically by 5.9%, and Hygiene has demonstrated further momentum, growing organically by 4.8%. Our performance in Q3, combined with further progress in our value-creating M&A programme, means we remain on track to meet expectations for the full year.

"I am also delighted to see the excellent results of our colleague survey. We continue to deliver world-class standards of colleague engagement and enablement, and we see this in turn resulting in outstanding service for our customers and higher levels of retention. I'd like to thank all of our colleagues for their ongoing commitment and determination to be the best at what we do."

 

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2018 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBLBDGUUBBGCL
Date   Source Headline
15th Feb 20195:15 pmRNSHolding(s) in Company
1st Feb 20197:00 amRNSChange to Director's details
4th Dec 20187:00 amRNSDefined benefit pension scheme buy-in with PIC
20th Nov 20185:17 pmRNSHolding(s) in Company
16th Nov 20184:14 pmRNSHolding(s) in Company
24th Oct 20182:36 pmRNSDirector/PDMR Shareholding
18th Oct 20187:00 amRNSQ3 Trading Update
2nd Oct 201812:17 pmRNSBlock listing Interim Review
25th Sep 20187:25 amRNSDirector Declaration
13th Sep 20184:43 pmRNSDirector/PDMR Shareholding
29th Aug 20187:00 amRNSDirector/PDMR Shareholding
20th Aug 201812:44 pmRNSDirector/PDMR Shareholding
1st Aug 20183:12 pmRNSHolding(s) in Company
31st Jul 20187:00 amRNSInterim Results
27th Jul 20185:07 pmRNSHolding(s) in Company
5th Jul 20184:52 pmRNSHolding(s) in Company
5th Jul 201811:36 amRNSDirector Declaration
28th Jun 20184:10 pmRNSHolding(s) in Company
7th Jun 20185:16 pmRNSDirector Declaration
17th May 20184:12 pmRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSNotice of Capital Markets Days
9th May 20185:40 pmRNSResult of AGM
4th May 20184:27 pmRNSDirector/PDMR Shareholding
2nd May 201810:52 amRNSDirector/PDMR Shareholding
1st May 20186:00 pmRNSDirector/PDMR Shareholding
30th Apr 20185:48 pmRNSDirector/PDMR Shareholding
26th Apr 20183:24 pmRNSHolding(s) in Company
25th Apr 20184:50 pmRNSHolding(s) in Company
24th Apr 20183:55 pmRNSHolding(s) in Company
24th Apr 201810:53 amRNSHolding(s) in Company
20th Apr 20184:09 pmRNSDirector/PDMR Shareholding
19th Apr 20184:32 pmRNSHolding(s) in Company
19th Apr 20187:00 amRNSQ1 Trading Update
5th Apr 201812:57 pmRNSHolding(s) in Company
5th Apr 201811:06 amRNSAnnual Financial Report
4th Apr 20186:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:12 pmRNSBlock listing Interim Review
29th Mar 201811:55 amRNSTotal Voting Rights
27th Mar 20184:01 pmRNSHolding(s) in Company
27th Mar 201812:58 pmRNSAdditional Listing
8th Mar 20185:50 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSFinal Results
27th Dec 20177:00 amRNSDirector/PDMR Shareholding
20th Dec 20173:40 pmRNSDirector/PDMR Shareholding
22nd Nov 20174:30 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSIssue of new EUR400m bond
13th Nov 20174:35 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSPurchase of Vector Disease Acquisition LLC
7th Nov 20174:14 pmRNSHolding(s) in Company
6th Nov 20177:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.